Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer Patients

NCT07924046 is registered in ClinicalTrials.gov with University of Lausanne Hospitals as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07924046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of Muscle Invasion and Detection of Residual Tumour in Non-muscle-invasive Bladder Cancer Patients
Lead sponsor
University of Lausanne Hospitals
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
March 31, 2028
Enrollment
86 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nmibc, turbt, urinary bladder cancer, vi-rads

Arms

As registered; 1 arm.

  • Multiparametric Magnetic Resonance Imaging ExperimentalMultiparametric Magnetic Resonance Imaging of the Bladder

    Participants with suspected bladder cancer will undergo multiparametric magnetic resonance imaging before transurethral resection of bladder tumour. Patients requiring repeat resection according to clinical indications will undergo a second magnetic resonance imaging examination approximately 3-4 weeks after the initial resection. Imaging findings will be compared with histopathological results to assess diagnostic performance.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Diagnostic Performance Approximately 3-4 weeks after initial transurethral resection, before repeat resection when clinically indicated.

    Diagnostic accuracy metrics (sensitivity, specificity, positive predictive value \[PPV\], and negative predictive value \[NPV\]) of mpMRI performed 3-4 weeks after initial TURBT for detecting residual bladder tumour, using histopathology as the reference standard.

Lead sponsor's other trials

University of Lausanne Hospitals, most recent start first.

Similar trials

Same condition (Non-Muscle Invasive Bladder Neoplasms) and phase, most recent start first.